A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.
Clinical trial NCT02914275 · COMPLETED
Trial details
- NCT number
- NCT02914275
- Sponsor
- Seqirus
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-09-27
- Primary completion
- 2017-03-09
- Enrollment
- 2250
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.